GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » Cash Conversion Cycle

LeMaitre Vascular (LeMaitre Vascular) Cash Conversion Cycle : 324.64 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is LeMaitre Vascular Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

LeMaitre Vascular's Days Sales Outstanding for the three months ended in Dec. 2023 was 45.68.
LeMaitre Vascular's Days Inventory for the three months ended in Dec. 2023 was 302.64.
LeMaitre Vascular's Days Payable for the three months ended in Dec. 2023 was 23.68.
Therefore, LeMaitre Vascular's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 324.64.


LeMaitre Vascular Cash Conversion Cycle Historical Data

The historical data trend for LeMaitre Vascular's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LeMaitre Vascular Cash Conversion Cycle Chart

LeMaitre Vascular Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 323.02 331.54 304.63 306.49 294.34

LeMaitre Vascular Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 297.91 293.54 277.61 302.62 324.64

Competitive Comparison of LeMaitre Vascular's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LeMaitre Vascular's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where LeMaitre Vascular's Cash Conversion Cycle falls into.



LeMaitre Vascular Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

LeMaitre Vascular's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=44.43+268.14-18.23
=294.34

LeMaitre Vascular's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=45.68+302.64-23.68
=324.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LeMaitre Vascular  (NAS:LMAT) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


LeMaitre Vascular Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


LeMaitre Vascular (LeMaitre Vascular) Business Description

Traded in Other Exchanges
Address
63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Executives
George W Lemaitre director, 10 percent owner, officer: Chairman, President and CEO 342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
Bridget A Ross director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
John A Roush director C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Lawrence J Jasinski director SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
David B Roberts director, officer: CFO and Director 55 BRADFORD STREET, NEEDHAM MA 02492
Trent G Kamke officer: Senior V. P., Operations 61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Pellegrino Joseph P Jr officer: Executive V.P. Finance 68 BEACON STREET, BOSTON MA 02108
Michael H Thomas director P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer officer: President, International OP AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas officer: VP of Sales, The Americas C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W director, officer: V.P., Human Resources,Director 8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays director C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden officer: VP, North American Sales 236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr director HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199